We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
We have the tenacity
to carry your innovations forward
Ipsen Key Facts
Impact across the globe
Represented in 88 countries, our commercial sales have strong coverage across North America (33%), Europe (40%), and the rest of world (27%) with our medicines showing best-in-class commercial performance.
Our North America base has grown rapidly: 600% over the last 6 years reaching >$1bn in 2022.
Strength in numbers: a strong pipeline
Since 2020, Ipsen has brought in over 20 best- or first-in-class programs across our pipeline at every stage of development and plans are in place to acquire more.
We are focused. We invest in opportunities in challenging disease areas to better address challenges faced by the community.
Acquiring Epizyme & Tazverik®
Ipsen acquired Epizyme in 2022, and with it Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, strengthening our oncology pipeline and reinforcing our focus on solid tumors and hematological malignancies.
Integrating Albireo & Bylvay®
In 2023, Ipsen acquired Albireo, accelerating our growth in rare disease with treatments for pediatric liver diseases. With Bylvay® (odevixibat), we boost our expertise in treating pruritus in young people with progressive familial intrahepatic cholestasis (PFIC). With Bylvay® (odevixibat) we boost our expertise in rare liver diseases in progressive familial intrahepatic cholestasis (PFIC) and Alagille Syndrome. The Phase III BOLD study in Biliary Atresia remains ongoing. This partnership also results in a number of other assets joining our clinical pipeline.
Recognition on the global stage
Ipsen was named SCRIP’s 2023 BD Team of the Year and 2022 Pharma BD Team of the year at the European Lifestars Award.
Focused and fast
Guided by our strategy, we move fast to make deals with like-minded partners. That’s how we were able to make two acquisitions in less than nine months.
Contact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Partnering events
Throughout the year, Ipsen holds numerous events for and with partners. Look through our upcoming events if you are interested in our work and in partnering with us and would like to meet our team.
Financial results for the first half of 2024
The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.
Our 2023 Integrated Annual Report is live!
In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.
Navigating Proactive Sustainability in Pharma R&D and Partnering
In March, we were proud to see Florence Dal Degan, Senior Director of External Innovation, participate in a panel discussion with different stakeholders, from consulting firms, pharma companies, investors to startups at BioEurope Spring entitled “Towards a Greener Globe: Biopharma’s Path to Sustaina
Q1 2024 sales update
The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.
Unlocking Potential Through Early-Stage Partnerships
We are pleased to share a recent conversation with Mary Jane Hinrichs, Senior Vice President, and Global Head of Early Development. Mary Jane spearheads the strategic direction and execution of early-stage programs at Ipsen, guiding them from drug candidate to…
Applications now open for the 2024 Golden Ticket competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through our continued partnership with BioLabs, we’re delighted to be offering the brightest minds in biotech…
Focus; Confidence; Commitment – The Building Blocks of Win-Win Partnerships
Ipsen’s Senior Director of Global Partnering for Oncology, Madee Gooriah, is part of the team leading efforts to expand Ipsen’s oncology franchise through external partnerships at every stage of development. But in an industry marked by complexity, how do we…
FY 2023 results announcement
Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.
J.P. Morgan 2024: Ipsen discusses progress, next phase of growth and partnering ambition
At the J.P. Morgan Healthcare Conference in San Francisco from January 8 to 11, 2024, Ipsen’s management team leaders will discuss our transformation story, next phase of growth and external innovation ambitions.
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.